BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

First Deal Under Business Development Push

 
• By Mandy Jackson
  
BioMarin is assessing several deals in addition to Inozyme (Shutterstock)

More from Deals

More from Scrip